Wave Life Sciences Ltd. Ordinary Shares (WVE)

FairStock Score: 27/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I see Wave Life Sciences as a clinical-stage RNA medicine company, not a proven business. Its PRISM platform and pipeline in obesity, AATD, and PNPLA3 liver disease may hold scientific promise, but the financial record shows no durable moat yet. In fiscal 2025, the year ended 2025-12-31, revenue was $42.7 million, down from $108.3 million in fiscal 2024, while net loss widened to $204.4 million from $97.0 million. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was only $2.3 million and net loss was $69.4 million. FairStock's trailing free cash flow was -$193.1 million, a -31.2% yield against the $618.7 million market cap at the 2026-10-13 close. FairStock also shows ROE of -67.42%, ROCE of -33.60%, Piotroski 1/9, and Altman Z 0.53, figures that suggest distress. The debt-to-equity ratio of 0.10 is low, but cash burn is the real issue. Valuation gives little comfort: FairStock's P/E is -2.91, and P/B is 1.14 at that close, so the $3.14 price is near accounting book value. A Graham margin of safety needs predictable earnings or solid asset protection; here value depends on clinical outcomes and financing. With losses in each of the last four years, the Lynch category is none. The shares sit near the 52-week low of $3.07 versus the high of $21.73. This is an option on science, not a classic value investment.

In plain English: Wave Life Sciences is a clinical-stage biotech developing RNA medicines for conditions like obesity and liver disease, but it has no profitable products yet. The business looks weak because it brings in little revenue, loses large amounts of money, and spends heavily. At $3.14 it is near its 52-week low, but with no profits it is hard to call the price clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer